YHO 1701
Alternative Names: YHO-1701Latest Information Update: 28 Dec 2022
At a glance
- Originator Yakult Honsha
- Developer University of Shizuoka; Yakult Honsha
- Class Antineoplastics
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in Japan (PO)
- 13 Nov 2018 Preclinical trials in Cancer in Japan (PO) before November 2018 (3364481; 3364492)
- 13 Nov 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018) (3364481; 3364492)